icon
icon
icon
icon
$300 Off
$300 Off

News /

Articles /

Eli Lilly Drops 4.82% as Zepbound Sales Miss Expectations

Mover TrackerMonday, Apr 7, 2025 4:57 am ET
1min read

On April 7, 2025, Eli Lilly's stock dropped 4.82% in pre-market trading, reflecting investor concerns over the company's recent financial performance and market outlook.

Eli Lilly, a leading player in the weight loss drug market, faced a significant setback with its flagship product Zepbound. The drug's third-quarter sales fell short of market expectations, raising concerns about the overall demand for weight loss medications. This news came as a shock to investors who had been optimistic about the potential of the weight loss drug market, which is projected to reach a trillion dollars by the end of the decade.

Despite the disappointing performance of Zepbound, Eli Lilly's CEO dave Ricks reassured investors that the market demand for these drugs remains strong. He attributed the sales shortfall to inventory management issues by wholesalers, who had reduced their stock levels of Zepbound and Mounjaro, another of the company's diabetes treatment drugs. Ricks emphasized that the company is not yet engaged in demand-stimulating activities, such as advertising, and plans to start these efforts in November. Additionally, eli lilly is investing heavily in its direct-to-consumer website, which offers remote medical prescriptions and home delivery of certain medications, aiming to expand patient access.

Analysts have mixed reactions to Eli Lilly's explanation. Some, like Geoff Meacham from Citigroup, agree that the inventory reduction is the primary cause of the sales drop, rather than a decline in demand. Others, such as Carter Gould from Barclays, believe that inventory issues account for only a small portion of the revenue decline. Despite these concerns, Eli Lilly remains optimistic about the future of its weight loss drugs, with ongoing research and development efforts aimed at improving the efficacy and accessibility of its products.

Comments

Add a public comment...
Post
User avatar and name identifying the post author
Snorkx
04/07
$SGMO Sangamo Therapeutics: Its Impact Goes Further Than the Recent $LLY Eli LiLLY Partnership https://seekingalpha.com/article/4773085-sangamo-therapeutics-scope-goes-beyond-that-of-recent-eli-lilly-licensing-deal?gt=f371f86a04eb6546
0
Reply
User avatar and name identifying the post author
cruelmeatdestroyer
04/07
@Snorkx 👍
0
Reply
User avatar and name identifying the post author
SussyAltUser
04/07
$LLY All you guys got a little too grabby.
0
Reply
User avatar and name identifying the post author
Amalekk
04/07
Eli LiLLY's stock drop is like a party where the host insists everyone's coming, but the guest list is empty
0
Reply
User avatar and name identifying the post author
wtfislandfill
04/07
@Amalekk Looks like Eli LiLLY's party's got the wrong invite list. Maybe they should YOLO on some new marketing moves?
0
Reply
User avatar and name identifying the post author
goldeneye700
04/07
LLY's got potential, patience is key
0
Reply
User avatar and name identifying the post author
AlmightyAntwan12
04/07
Zepbound dip = buying op? 🚀
0
Reply
User avatar and name identifying the post author
AquafreshBandit
04/07
@AlmightyAntwan12 How long u holding? Thinking of a short-term trade myself.
0
Reply
User avatar and name identifying the post author
roycheung0319
04/07
M&A activity heating up, who's next?
0
Reply
User avatar and name identifying the post author
EL-Vinci93
04/07
@roycheung0319 Who do you think?
0
Reply
User avatar and name identifying the post author
serenitybybowie
04/07
OMG!I successfully capitalized on the LLY stock's bearish trend, generating $495!
0
Reply
Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.
You Can Understand News Better with AI.
Whats the News impact on stock market?
Its impact is
fork
logo
AInvest
Aime Coplilot
Invest Smarter With AI Power.
Open App